Seek Returns logo

ALHC vs. MDGL: A Head-to-Head Stock Comparison

Updated on

Here’s a clear look at ALHC and MDGL, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.

Company Overview

MDGL’s market capitalization of 6.64 billion USD is significantly greater than ALHC’s 2.68 billion USD, highlighting its more substantial market valuation.

ALHC has a positive beta (1.22), indicating it generally moves with the broader market, whereas MDGL has a negative beta (-1.08), often moving inversely, which can offer diversification or hedging benefits.

SymbolALHCMDGL
Company NameAlignment Healthcare, Inc.Madrigal Pharmaceuticals, Inc.
CountryUSUS
SectorHealthcareHealthcare
IndustryMedical - Healthcare PlansBiotechnology
CEOJohn E. KaoWilliam J. Sibold
Price13.57 USD298.87 USD
Market Cap2.68 billion USD6.64 billion USD
Beta1.22-1.08
ExchangeNASDAQNASDAQ
IPO DateMarch 26, 2021February 6, 2007
ADRNoNo

Historical Performance

This chart compares the performance of ALHC and MDGL by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period.

Data is adjusted for dividends and splits.

ALHC vs. MDGL: Growth of a $10,000 investment over the past one year.

Profitability

Return on Equity

ALHC

-81.24%

Medical - Healthcare Plans Industry

Max
13.94%
Q3
13.62%
Median
11.42%
Q1
7.74%
Min
6.98%

ALHC has a negative Return on Equity of -81.24%. This indicates the company is generating a loss for its shareholders, which can be a result of unprofitability or negative shareholder equity and is often a sign of financial distress.

MDGL

-50.54%

Biotechnology Industry

Max
72.39%
Q3
-6.30%
Median
-32.82%
Q1
-68.26%
Min
-147.61%

MDGL has a negative Return on Equity of -50.54%. This indicates the company is generating a loss for its shareholders, which can be a result of unprofitability or negative shareholder equity and is often a sign of financial distress.

ALHC vs. MDGL: A comparison of their ROE against their respective Medical - Healthcare Plans and Biotechnology industry benchmarks.

Return on Invested Capital

ALHC

-15.02%

Medical - Healthcare Plans Industry

Max
15.50%
Q3
7.12%
Median
5.48%
Q1
-3.47%
Min
-15.02%

ALHC has a negative Return on Invested Capital of -15.02%. This indicates that its operations are failing to generate a profit on the total capital invested, signaling significant inefficiency or value destruction.

MDGL

-51.26%

Biotechnology Industry

Max
48.74%
Q3
-10.68%
Median
-31.65%
Q1
-52.92%
Min
-113.69%

MDGL has a negative Return on Invested Capital of -51.26%. This indicates that its operations are failing to generate a profit on the total capital invested, signaling significant inefficiency or value destruction.

ALHC vs. MDGL: A comparison of their ROIC against their respective Medical - Healthcare Plans and Biotechnology industry benchmarks.

Net Profit Margin

ALHC

-3.02%

Medical - Healthcare Plans Industry

Max
3.23%
Q3
2.62%
Median
1.70%
Q1
1.27%
Min
1.22%

ALHC has a negative Net Profit Margin of -3.02%, indicating the company is operating at a net loss as its expenses exceeded its revenues.

MDGL

-123.38%

Biotechnology Industry

Max
87.75%
Q3
-5.05%
Median
-103.44%
Q1
-1,032.77%
Min
-2,366.07%

MDGL has a negative Net Profit Margin of -123.38%, indicating the company is operating at a net loss as its expenses exceeded its revenues.

ALHC vs. MDGL: A comparison of their Net Profit Margin against their respective Medical - Healthcare Plans and Biotechnology industry benchmarks.

Operating Profit Margin

ALHC

-2.19%

Medical - Healthcare Plans Industry

Max
4.30%
Q3
3.77%
Median
2.61%
Q1
1.60%
Min
-1.64%

ALHC has a negative Operating Profit Margin of -2.19%. This signifies the company is unprofitable at the operational level, as its core business expenses exceed its revenue.

MDGL

-133.95%

Biotechnology Industry

Max
87.75%
Q3
-3.28%
Median
-115.26%
Q1
-1,188.86%
Min
-2,943.30%

MDGL has a negative Operating Profit Margin of -133.95%. This signifies the company is unprofitable at the operational level, as its core business expenses exceed its revenue.

ALHC vs. MDGL: A comparison of their Operating Margin against their respective Medical - Healthcare Plans and Biotechnology industry benchmarks.

Profitability at a Glance

SymbolALHCMDGL
Return on Equity (TTM)-81.24%-50.54%
Return on Assets (TTM)-10.12%-39.29%
Return on Invested Capital (TTM)-15.02%-51.26%
Net Profit Margin (TTM)-3.02%-123.38%
Operating Profit Margin (TTM)-2.19%-133.95%
Gross Profit Margin (TTM)11.57%96.67%

Financial Strength

Current Ratio

ALHC

1.69

Medical - Healthcare Plans Industry

Max
1.91
Q3
1.63
Median
1.43
Q1
0.85
Min
0.78

ALHC’s Current Ratio of 1.69 is in the upper quartile for the Medical - Healthcare Plans industry. This signifies a strong liquidity position, suggesting the company is well-equipped to cover its immediate liabilities compared to its peers.

MDGL

5.91

Biotechnology Industry

Max
28.73
Q3
13.97
Median
6.31
Q1
3.60
Min
0.02

MDGL’s Current Ratio of 5.91 aligns with the median group of the Biotechnology industry, indicating that its short-term liquidity is in line with its sector peers.

ALHC vs. MDGL: A comparison of their Current Ratio against their respective Medical - Healthcare Plans and Biotechnology industry benchmarks.

Debt-to-Equity Ratio

ALHC

0.07

Medical - Healthcare Plans Industry

Max
1.06
Q3
0.86
Median
0.75
Q1
0.66
Min
0.66

At 0.07, ALHC’s Debt-to-Equity Ratio is unusually low for the Medical - Healthcare Plans industry. This highlights a conservative capital structure, suggesting the company prioritizes financial stability over aggressive growth funded by debt.

MDGL

0.17

Biotechnology Industry

Max
0.46
Q3
0.22
Median
0.06
Q1
0.02
Min
0.00

MDGL’s Debt-to-Equity Ratio of 0.17 is typical for the Biotechnology industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.

ALHC vs. MDGL: A comparison of their D/E Ratio against their respective Medical - Healthcare Plans and Biotechnology industry benchmarks.

Interest Coverage Ratio

ALHC

-2.98

Medical - Healthcare Plans Industry

Max
6.23
Q3
6.23
Median
5.19
Q1
4.64
Min
3.18

ALHC has a negative Interest Coverage Ratio of -2.98. This indicates that its earnings were insufficient to cover even its operational costs, let alone its interest payments, signaling significant financial distress.

MDGL

-30.09

Biotechnology Industry

Max
108.32
Q3
-0.55
Median
-8.49
Q1
-74.83
Min
-168.36

MDGL has a negative Interest Coverage Ratio of -30.09. This indicates that its earnings were insufficient to cover even its operational costs, let alone its interest payments, signaling significant financial distress.

ALHC vs. MDGL: A comparison of their Interest Coverage against their respective Medical - Healthcare Plans and Biotechnology industry benchmarks.

Financial Strength at a Glance

SymbolALHCMDGL
Current Ratio (TTM)1.695.91
Quick Ratio (TTM)1.695.58
Debt-to-Equity Ratio (TTM)0.070.17
Debt-to-Asset Ratio (TTM)0.010.12
Net Debt-to-EBITDA Ratio (TTM)10.900.17
Interest Coverage Ratio (TTM)-2.98-30.09

Growth

The following charts compare key year-over-year (YoY) growth metrics for ALHC and MDGL. These metrics are based on the companies’ annual financial reports.

Revenue Growth

ALHC vs. MDGL: A comparison of their annual year-over-year Revenue Growth.

Earnings Per Share (EPS) Growth

ALHC vs. MDGL: A comparison of their annual year-over-year Earnings Per Share (EPS) Growth.

Free Cash Flow Growth

ALHC vs. MDGL: A comparison of their annual year-over-year Free Cash Flow Growth.

Dividend

Dividend Yield

ALHC

0.00%

Medical - Healthcare Plans Industry

Max
3.88%
Q3
1.78%
Median
0.73%
Q1
0.00%
Min
0.00%

ALHC currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.

MDGL

0.00%

Biotechnology Industry

Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

MDGL currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.

ALHC vs. MDGL: A comparison of their Dividend Yield against their respective Medical - Healthcare Plans and Biotechnology industry benchmarks.

Dividend Payout Ratio

ALHC

0.00%

Medical - Healthcare Plans Industry

Max
63.88%
Q3
29.91%
Median
12.57%
Q1
0.00%
Min
0.00%

ALHC has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.

MDGL

0.00%

Biotechnology Industry

Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

MDGL has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.

ALHC vs. MDGL: A comparison of their Payout Ratio against their respective Medical - Healthcare Plans and Biotechnology industry benchmarks.

Dividend at a Glance

SymbolALHCMDGL
Dividend Yield (TTM)0.00%0.00%
Dividend Payout Ratio (TTM)0.00%0.00%

Valuation

Price-to-Earnings Ratio

ALHC

-28.99

Medical - Healthcare Plans Industry

Max
18.17
Q3
17.32
Median
15.48
Q1
13.55
Min
12.84

ALHC has a negative P/E Ratio of -28.99. This occurs when a company has negative earnings (a net loss), making the ratio unsuitable for valuation analysis.

MDGL

-16.86

Biotechnology Industry

Max
78.44
Q3
48.98
Median
20.50
Q1
12.64
Min
2.14

MDGL has a negative P/E Ratio of -16.86. This occurs when a company has negative earnings (a net loss), making the ratio unsuitable for valuation analysis.

ALHC vs. MDGL: A comparison of their P/E Ratio against their respective Medical - Healthcare Plans and Biotechnology industry benchmarks.

Forward P/E to Growth Ratio

ALHC

-0.99

Medical - Healthcare Plans Industry

Max
1.41
Q3
1.09
Median
0.85
Q1
0.79
Min
0.60

ALHC has a negative Forward PEG Ratio of -0.99. This typically results from negative earnings or forecasts of declining future earnings, making the ratio not meaningful for valuation.

MDGL

-0.91

Biotechnology Industry

Max
2.29
Q3
1.10
Median
0.49
Q1
0.16
Min
0.02

MDGL has a negative Forward PEG Ratio of -0.91. This typically results from negative earnings or forecasts of declining future earnings, making the ratio not meaningful for valuation.

ALHC vs. MDGL: A comparison of their Forward PEG Ratio against their respective Medical - Healthcare Plans and Biotechnology industry benchmarks.

Price-to-Sales Ratio

ALHC

0.89

Medical - Healthcare Plans Industry

Max
0.94
Q3
0.64
Median
0.43
Q1
0.27
Min
0.16

ALHC’s P/S Ratio of 0.89 is in the upper echelon for the Medical - Healthcare Plans industry. This means the company is valued richly on its revenue stream compared to its peers, suggesting the stock is priced for a high level of future performance.

MDGL

20.91

Biotechnology Industry

Max
110.90
Q3
59.76
Median
11.33
Q1
4.45
Min
0.17

MDGL’s P/S Ratio of 20.91 aligns with the market consensus for the Biotechnology industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.

ALHC vs. MDGL: A comparison of their P/S Ratio against their respective Medical - Healthcare Plans and Biotechnology industry benchmarks.

Price-to-Book Ratio

ALHC

24.30

Medical - Healthcare Plans Industry

Max
4.08
Q3
3.83
Median
2.63
Q1
1.74
Min
0.96

At 24.30, ALHC’s P/B Ratio is at an extreme premium to the Medical - Healthcare Plans industry. This signifies that the market’s valuation is heavily reliant on future potential rather than its current net asset value, which can be a high-risk proposition.

MDGL

9.29

Biotechnology Industry

Max
15.78
Q3
7.44
Median
3.31
Q1
1.58
Min
0.31

The P/B Ratio is often not a primary valuation metric for the Biotechnology industry.

ALHC vs. MDGL: A comparison of their P/B Ratio against their respective Medical - Healthcare Plans and Biotechnology industry benchmarks.

Valuation at a Glance

SymbolALHCMDGL
Price-to-Earnings Ratio (P/E, TTM)-28.99-16.86
Forward PEG Ratio (TTM)-0.99-0.91
Price-to-Sales Ratio (P/S, TTM)0.8920.91
Price-to-Book Ratio (P/B, TTM)24.309.29
Price-to-Free Cash Flow Ratio (P/FCF, TTM)140.75-16.53
EV-to-EBITDA (TTM)-55.82-17.47
EV-to-Sales (TTM)0.7520.71